BJD Editor's Choice  by unknown
BJD EDITOR'S CHOICE
© 2015 British Association of Dermatologists www.jidonline.org 647
from the British Journal of Dermatology
Assessment of the elicitation response 
in subjects weakly sensitized to 
p-phenylenediamine
Pot et al. explain that p-phenylenediamine (PPD) is well 
recognized as one of the potent sensitizers responsible for 
allergic contact dermatitis occurring in relation to hair dye-
ing. This paper includes a detailed assessment of the elicita-
tion response under differing exposure conditions, related 
to the corresponding exposure levels, in individuals who 
had a weak response to a patch test with PPD. Additionally, 
the authors interviewed subjects to address the topics of 
temporary ‘black henna tattoos’ and the hairdressing pro-
fession, because of the very strong relationship with expo-
sure to PPD. To evaluate PPD patch test results accurately, 
concomitant positive patch test reactions were recorded. 
The authors showed that by combining elicitation data with 
measured PPD exposure levels, a range of exposure condi-
tions could be established, within which responses can be 
elicited in a number of subjects weakly sensitized to PPD. 
They concluded that this confirms that exposure dose and 
time determine the measured exposure levels and thus the 
threshold of the elicitation response. Br J Dermatol 2015; 
172: 138–144.
Fractional laser-mediated photodynamic 
therapy of high-risk basal cell carcinomas – a 
randomized clinical trial
Haak et al., from Bispebjerg Hospital at the University of 
Copenhagen, Denmark, explain that photodynamic therapy 
(PDT) is approved for treatment of selected nodular basal 
cell carcinomas (BCCs), but that efficacy is reduced for 
large and thick tumours. However, ablative fractional lasers 
may facilitate the uptake of methyl aminolaevulinate and 
may thus improve PDT outcome. Their study explored the 
efficacy of fractional laser-mediated PDT compared with 
conventional PDT for the first time in a randomized clini-
cal trial for high-risk nodular BCC. They conclude that the 
long-term efficacy was similar after conventional PDT and 
fractional laser-mediated PDT, with a trend for a more 
favourable short-term cure rate after the fractional laser-
mediated PDT. However, they also conclude that fractional 
laser-mediated PDT needs further refinement for nodular 
BCCs and at present is not recommended over conventional 
PDT. Br J Dermatol 2015; 172: 215–222.
Pattern of response in patients with moderate-
to-severe psoriasis treated with etanercept
This study from Griffiths et al. from Manchester, U.K. reveals 
that for patients with moderate-to-severe psoriasis, 75% 
improvements are achieved faster with etanercept given 
as 50 mg twice weekly than 50 mg once weekly for all 
Psoriasis Area and Severity Index body regions and compo-
nents. Furthermore, etanercept reduces skin disease signs 
most quickly on the head and trunk, with the fastest respons-
es observed in the components of desquamation and indu-
ration. Finally, the authors conclude that recognition of the 
pattern of treatment response could help to predict future 
outcomes and manage patient expectations. Br J Dermatol 
2015; 172: 230–238.
Patients treated with BRAF inhibitor-based 
therapies for metastatic melanoma require 
long-term dermatological follow-up
Anforth et al. from the Westmead Institute for Cancer 
Research in New South Wales, Australia explain that BRAF 
inhibitor-based therapies induce cutaneous toxicities, gener-
ally in the first 8–26 weeks of therapy. Their objectives in this
study were to determine whether cutaneous toxicities 
persist in patients who have remained on BRAF inhibitor-
based therapies for longer than 52 weeks, and therefore 
whether ongoing dermatology assessment is required. They 
discovered that patients continued to develop cutaneous 
adverse events after 52 weeks of continuous therapy. The 
most frequent adverse event reported was for patients treat-
ed with both BRAF and mitogen-activated protein kinase 
kinase inhibitors, where 40% developed an acneiform 
eruption. They concluded that patients on BRAF inhibitor-
based therapies require regular dermatological follow-up 
independent of the duration of their therapy. Br J Dermatol 
2015; 172: 239–243.
